Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 519.82%.

  • Aclaris Therapeutics' EBIT Margin fell 2788900.0% to 519.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 973.93%, marking a year-over-year decrease of 8029400.0%. This contributed to the annual value of 758.18% for FY2024, which is 4466300.0% down from last year.
  • Per Aclaris Therapeutics' latest filing, its EBIT Margin stood at 519.82% for Q3 2025, which was down 2788900.0% from 1035.9% recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year EBIT Margin high stood at 23.03% for Q4 2023, and its period low was 1702.25% during Q2 2023.
  • Moreover, its 5-year median value for EBIT Margin was 1035.9% (2025), whereas its average is 901.37%.
  • The largest annual percentage gain for Aclaris Therapeutics' EBIT Margin in the last 5 years was 12375300bps (2024), contrasted with its biggest fall of -10591000bps (2024).
  • Aclaris Therapeutics' EBIT Margin (Quarter) stood at 1525.18% in 2021, then surged by 75bps to 375.07% in 2022, then surged by 94bps to 23.03% in 2023, then crashed by -4598bps to 1082.13% in 2024, then skyrocketed by 52bps to 519.82% in 2025.
  • Its last three reported values are 519.82% in Q3 2025, 1035.9% for Q2 2025, and 1242.89% during Q1 2025.